Digestive Disease Interventions 2020; 04(04): 343-344
DOI: 10.1055/s-0040-1721798
Preface

Immuno-Oncology and Interventional Oncology

Hyun S. Kim
1  Section of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, Connecticut New Haven, Connecticut
2  Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, Connecticut New Haven, Connecticut
3  Yale Cancer Center, Yale School of Medicine, New Haven, New Haven, Connecticut
› Author Affiliations
Zoom Image
Hyun S. Kim, MD, MHS

Immuno-oncology (IO1) with immune checkpoint inhibitors (ICI) is one of the most important milestones in cancer medicine discovery and has emerged at the forefront of therapy for advanced cancers. Early studies of immunotherapies with ICI of the CTLA-4 and the PD-1/PD-L1 axis have shown efficacy in solid cancers of melanoma, lung and genitourinary cancers. Recently, active investigations in advanced gastrointestinal and hepatobiliary cancers, including hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, gastroesophageal cancer and colorectal cancer, have shown promising results with IO1.

Interventional oncology (IO2) with sophisticated local therapies for local tumor control can play an important role in reducing tumor burden, thereby improving the disease control rates and overall outcomes. Significant advancements in local therapy, beyond the obvious local benefit, have demonstrated the potential to induce an in situ antitumor immunostimulatory process in several solid tumors.

Combining IO1 and IO2 therapies could result in an ideal treatment strategy to enhance patient benefits. Significant works are currently underway in basic and translational research, biology, biomarkers, imaging, and techniques for IO1 + IO2 treatment strategies to be used in advanced cancers. Basic scientific findings in relation to immune-modulation strategies of IO1 + IO2 with effective antitumor immune response are also under investigations in clinical trials, and it may potentially further enhance immunotherapeutic strategies and patient outcomes.

The field of IO1 + IO2 is novel, and although there have been remarkable developments and advances in it, there is still a lot of work ahead in this complex, challenging and yet exciting sphere. With advances in sophisticated systemic and local cancer therapies, clinical care in advanced metastatic digestive disease cancers in the real world are not only of significant interest but also represent unmet needs.

Keeping this in mind, the special issue in Immuno-Oncology and Interventional Oncology in Digestive Disease Interventions is devoted to the science and evidence IO1 and IO2 therapies. It presents the rationale and provides clinical and research directions to immune therapy and local therapy approaches in the care of advanced digestive disease cancers.



Publication History

Publication Date:
21 December 2020 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA